Although the bone graft product market is inundated with more than 300 available products, only two have met the most stringent FDA requirements for spinal fusion indications and possess Level I data appearing in publications.
As private payers and CMS continue to require persuading evidence for coverage inclusion, healthcare organizations stand to benefit from selecting bone grafting material with generalizable proof of safety and efficacy.
During a Cerapedics-sponsored webinar, Michael E. Janssen, DO, Founder of Thornton, Colo.-based Center for Spine and Orthopedics, and Scott Johnson, PhD, Director of Clinical Marketing and Education at Cerapedics, will shed light on the varying levels of evidence in bone grafting and how this shapes clinical decision making.
Find out how your organization can wade through bone grafting product options based on supporting evidence and hear how Dr. Janssen leverages science and data behind products to enhance his practice and help his patients.
Tune in to clear up any misconceptions surrounding regulatory scrutiny and payer-mandated evidence and discover how the advanced biologic, i-FACTOR Peptide Enhanced Bone Graft, has redefined the category.
To register for the webinar on April 20, 2017, from 11 a.m. to 12 p.m. CT, click here.